Dogwood Therapeutics
Alpharetta
About Dogwood Therapeutics
Dogwood Therapeutics develops treatments for pain and fatigue-related illnesses. The company focuses on conditions such as chemotherapy-induced neuropathic pain, long COVID, and fibromyalgia. It is developing Halneuron, a sodium channel blocker for pain management, and antiviral combination therapies IMC-1 and IMC-2. Clinical trials are conducted to test the safety and effectiveness of these treatments. It also researches non-opioid solutions to address pain without addiction or withdrawal risks.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 11 – 50
- Estimated revenue: $10K – $50K
- Total funding: $64.1M
- Funding stage: IPO
- Last round: Post-IPO Equity (Jan 2026)
- Ticker: nasdaq:DWTX
- Website: dwtx.com
- Phone: (866) 620-9655
Industries & Categories
Biotechnology, Health Care, Mobile Apps, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/dogwood-therapeutics-96935 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.